Elite athletes and anticoagulant therapy: an intermittent dosing strategy
Authors:
- 30 November 2018
- journal article
- research article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2018 (1) , 412-417
Abstract
Traditionally, the athlete who requires long-term anticoagulation has been told to forgo participation in contact and collision sports. However, a strategy of short-term interruption of anticoagulant therapy may be designed for some athletes, allowing them return to full athletic activity. A personalized pharmacokinetic/pharmacodynamic study of a direct oral anticoagulant (DOAC) may allow athletic participation when plasma drug concentration is minimal and resumption of treatment after the risk of bleeding sufficiently normalizes. Scientific data and uncertainties regarding this approach, as well as practical challenges in the implementation, will be discussed.Keywords
This publication has 20 references indexed in Scilit:
- Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulantsJournal of Thrombosis and Haemostasis, 2018
- Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover studyJournal of Thrombosis and Haemostasis, 2017
- Athletes and blood clots: individualized, intermittent anticoagulation managementJournal of Thrombosis and Haemostasis, 2017
- Patient values and preferences for antithrombotic therapy in atrial fibrillationThrombosis and Haemostasis, 2017
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinicsThrombosis Research, 2016
- The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation PatientsJACC, 2014
- Clinical Pharmacokinetic and Pharmacodynamic Profile of RivaroxabanClinical Pharmacokinetics, 2013
- Patient Values and Preferences in Decision Making for Antithrombotic Therapy: A Systematic ReviewChest, 2012
- Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClinical Pharmacology & Therapeutics, 2005